Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. - Wikidata - wikimedia - TriplyDB

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.

http://www.wikidata.org/entity/Q38170576

about

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort Dolutegravir: clinical efficacy and role in HIV therapy.A new hypothesis on HIV cure.HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Wee Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054).Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.ARVs: the next generation. Going boldly together to new frontiers of HIV treatment.Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens.Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.Dolutegravir/rilpivirine for the treatment of HIV-1 infection

P2860

Q28540037-FF26DA15-134A-43FC-9BB4-6B5BD91C8208 Q28552719-BBCCAEC3-850F-4292-91A1-3242E6F83D7C Q33725024-8ED78277-5D23-4082-AF26-B7386837D6B1 Q36028475-C4F364D9-693F-42D7-BA38-03FF91E89486 Q36377132-58BC875F-5293-4A90-A788-B3EF2FAAAA14 Q36868170-59741888-DCAE-4ED1-A034-CCAFCCC9AA81 Q38821304-1B34CF75-F469-452D-BCC9-311822432D67 Q39352442-3665EE26-F917-427A-911F-75C3D84E767C Q41724352-A176FF53-3FD0-4982-8A35-FD58B08E5D4A Q41736369-F03D216C-6991-4657-99C0-3CDFC1B9E2E3 Q43183132-0A2BEEC1-C173-452B-B0FA-1F695E08917B Q47562735-2082C364-DB75-4688-A093-B413F5D38C32 Q55512944-BC38E4DD-44B1-419E-8196-F309361FC1D2 Q59135153-D712CD52-D9BF-4F8B-B720-9FD49977FEA7

P2860

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.

http://www.wikidata.org/entity/Q38170576

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Antiretroviral regimens sparin ...... view of the recent literature.

@en

type

label

Antiretroviral regimens sparin ...... view of the recent literature.

@en

prefLabel

Antiretroviral regimens sparin ...... view of the recent literature.

@en

P1433

Q38170576-261A0E6E-4401-401E-A6D9-26AB07AFC0CB

P1476

Q38170576-0420ED96-E7D9-4C0B-B43E-F9964E61554C

P2093

Q38170576-7E4A26E9-2D46-4AC3-88FA-6C1C5EB287B5

P2860

Q38170576-0412E534-FF39-42DA-AF9A-08F6A3442496

Q38170576-06E6F570-CE8A-4B7A-AA2A-9AF7FCED179E

Q38170576-0A6FFA01-F3D5-4D18-AB63-57958EF2F426

Q38170576-0C52558D-4D2E-4688-8F64-F97C61945E82

Q38170576-262066DE-14CE-4D46-AE66-96F040861082

Q38170576-306EE954-36B3-4AC2-8C9C-5CCED2F10A06

Q38170576-3623A5F5-F9A2-4351-8C5F-A888A0718670

Q38170576-3D42A489-23A2-4F5A-9076-4D33420CC5CA

Q38170576-4614A369-B4FB-4654-8E50-8B94F53BB036

Q38170576-4B221EB6-1AA1-4063-8131-CFA50EA25EB7

P2888

Q38170576-19F8BBB4-F9C7-45A1-A789-BE7688280F48

P304

Q38170576-656372BD-BBE2-40F8-BCBA-B1F330978FFB

P31

Q38170576-A818226C-377F-4B6E-8F9E-3968EDF618E5

P356

Q38170576-427B3E04-1B13-4F94-BE24-B3C80D2293C7

P433

Q38170576-CE94B429-B140-4C24-B902-4FA7E5B4FD70

P478

Q38170576-92A88A9E-A411-4E88-894A-F08D8D2783EF

P50

Q38170576-C65118C4-7235-4C5A-8F0C-6ABE2308178E

P577

Q38170576-CD038B6C-7231-4D9F-9B62-C85187A7243A

P5875

Q38170576-1B2B775F-C0B0-4B80-BA6C-794C08C97AB2

P6179

Q38170576-C90FE9D0-AD46-467E-A7B7-AF9647E799BC

P698

Q38170576-C226BEBA-2BED-40D8-8E0F-FD40B357D972

P921

Q38170576-705269A5-D0D2-4E7A-B4B5-CF06BF6E5166

P932

Q38170576-35891D01-09E2-404C-A7D7-656F5300DF0F

P356

1742-6405-10-33

P1433

AIDS Research and Therapy

P1476

Antiretroviral regimens sparin ...... view of the recent literature.

@en

P2093

Amit C Achhra

http://www.w3.org/2001/XMLSchema#string

P2860

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.

HLA-B*5701 screening for hypersensitivity to abacavir.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia

A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

P2888

1742-6405-10-33

P304

33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1742-6405-10-33

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259315707

http://www.w3.org/2001/XMLSchema#string

P6179

1005199625

http://www.w3.org/2001/XMLSchema#string

P698

24330617

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3874614

http://www.w3.org/2001/XMLSchema#string